Submitted:
13 February 2024
Posted:
13 February 2024
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
2.1. Study design and participants
2.2. Treatment
2.3. Product preparation
2.4. Efficacy assessment
2.5. Assessment of safety and tolerability
2.6. Statistical analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Informed Consent Statement
Conflicts of Interest
References
- de Lencastre Novaes, L.C.; Jozala, A.F.; Lopes, A.M.; de Carvalho Santos-Ebinuma, V.; Mazzola, P.G.; Pessoa Junior, A. Stability, purification, and applications of bromelain: A review. Biotechnol. Prog. 2016, 32, 5–13. [CrossRef]
- González-Rábade, N.; Badillo-Corona, J.A.; Aranda-Barradas, J.S.; del Carmen Oliver-Salvador, M. Production of plant proteases in vivo and in vitro—A review. Biotechnol. Adv. 2011, 29, 983–996. [CrossRef]
- Colletti, A.; Li, S.; Marengo, M.; Adinolfi, S.; Cravotto, G. Recent Advances and Insights into Bromelain Processing, Pharmacokinetics and Therapeutic Uses. Appl. Sci. 2021, 11, 8428. [CrossRef]
- Pavan, R.; Jain, S.; Shraddha; Kumar, A. Properties and Therapeutic Application of Bromelain: A Review. Biotechnol. Res. Int. 2012, 2012, 1–6. [CrossRef]
- Liu, S.; Zhao, H.; Wang, Y.; Zhao, H.; Ma, C. Oral Bromelain for the Control of Facial Swelling, Trismus, and Pain after Mandibular Third Molar Surgery: A Systematic Review and Meta-Analysis. J. Oral Maxillofac. Surg. 2019, 77, 1566–1574. [CrossRef]
- Mendes, M.; Nascimento-Junior, E.D.; Reinheimer, D.; Martins-Filho, P. Efficacy of proteolytic enzyme bromelain on health outcomes after third molar surgery. Systematic review and meta-analysis of randomized clinical trials. 2019, 24, e61–e69. [CrossRef]
- Almeida, R.D.A.; Lima, F.D.S.; Vasconcelos, B.D.E. Is bromelain an effective drug for the control of pain and inflammation associated with impacted third molar surgery? Systematic review and meta-analysis. Int. J. Oral Maxillofac. Surg. 2019, 48, 651–658. [CrossRef]
- De Souza, G.M.; Fernandes, I.A.; Dos Santos, C.R.R.; Falci, S.G.M. Is bromelain effective in controlling the inflammatory parameters of pain, edema, and trismus after lower third molar surgery? A systematic review and meta-analysis. Phytother. Res. 2019, 33, 473–481. [CrossRef]
- Weinstock, R.J.; Johnson, M.P. Review of Top 10 Prescribed Drugs and Their Interaction with Dental Treatment. Dent Clin North Am. 2016, 60(2):421-34. [CrossRef] [PubMed]
- de Martino, M.; Chiarugi, A.; Boner, A.; Montini, G.; De' Angelis, G.L. Working Towards an Appropriate Use of Ibuprofen in Children: An Evidence-Based Appraisal. Drugs. 2017,77(12):1295-1311. [CrossRef]
- Lewis, S.C.; Langman, M.J.; Laporte, J.R.; Matthews, J.N.; Rawlins, M.D.; Wiholm, B.E. Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data. British Journal of Clinical Pharmacology. 2002, 54: 320-6. [CrossRef]
- Strom, B.L.; Schinnar, R.; Bilker, W.B.; Feldman, H.; Farrar, J.T.; Carson, J.L. Gastrointestinal tract bleeding associated with naproxen sodium vs ibuprofen. Archives of Internal Medicine. 1997, 157: 2626-31. [CrossRef]
- Wolfe, M.M.; Lichtenstein, D.R.; Singh, G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. New England Journal of Medicine. 1999; 340: 1888-99. [CrossRef]
- Fissore, A.; Marengo, M.; Santoro, V.; Grillo, G.; Oliaro-Bosso, S.; Cravotto, G.; Dal Piazm, F.; Adinolfi, S. Processes 2023, 11, 2064. [CrossRef]
- Majid, O.W. Submucosal dexamethasone injection improves quality of life measures after third molar surgery: A comparative study. J Oral Maxillofac Surg 2011,69:2289. [CrossRef]
- Lordan, R. Dietary supplements and nutraceuticals market growth during the coronavirus pandemic – Implications for consumers and regulatory oversight, PharmaNutrition 2021, 100282. [CrossRef]
- Espín, J.C.; García-Conesa, M.T.; Tomas-Barber, F.A. Nutraceuticals: facts and fiction. Phytochemistry 2007, 68 (22–24) 2986–3008. [CrossRef]
- Smith, S. Global $275 Billion Nutraceuticals 2017–2021: New Applications for Probiotics, Genetic Modification and Diet as Products Make Gains in Rx Territory – ResearchAndMarkets.com, 2018〈https://www.businesswire.com/news/home/20180118005641/en/Global-275-Billion-Nutraceuticals-2017–2021-New-Applications-for-Probiotics-Genetic-Modification-and-Diet-as-Products-Make-Gains-in-Rx-Territory—ResearchAndMarkets.com.
- Faramarzi M, Sadighi M, Shirmohamadi A, Kazemi R, Zohdi M. Effectiveness of Bromelain in the control of postoperative pain after periodontal surgery: A crossover randomized clinical trial. J Adv Periodontol Implant Dent. 2023 15(1):22-27. [CrossRef]
- Kasemsuk T, Saengpetch N, Sibmooh N, Unchern S. Improved WOMAC score following 16-week treatment with bromelain for knee osteoarthritis. Clin Rheumatol. 2016 35(10):2531-40. [CrossRef]
- Carnevali, A.; Vaccaro, S.; Borselli, M.; Bousyf, S.; Lamonica, L.; Randazzo, G.; Giannaccare, G.; Scorcia, V. Anatomical and Functional Effects of an Oral Supplementation of Bromelain and Curcugreen in Patients with Focal Diabetic Macular Edema. J Clin Med. 2023, 12(23):7318. [CrossRef]
- Meena, L.; Sengar, A.S.; Neog, R.; Sunil, C.K. Pineapple processing waste (PPW): bioactive compounds, their extraction, and utilisation: a review. J Food Sci Technol. 2022, 59(11):4152-4164. [CrossRef]
- Majid, O.W.; Al-Mashhadani, BA. Perioperative bromelain reduces pain and swelling and improves quality of life measures after mandibular third molar surgery: a randomized, double-blind, placebo-controlled clinical trial. J Oral Maxillofac Surg. 2014, 72(6):1043-8. [CrossRef]
- Fitzhugh, D.J.; Shan, S.; Dewhirst, M.W.; Hale, L.P. Bromelain treatment decreases neutrophil migration to sites of inflammation. Clin. Immunol. 2008, 128, 66–74. [CrossRef]
- Tochi, B.N.; Wang, Z.; Xu, S.-.Y.; Zhang, W. Therapeutic Application of Pineapple Protease (Bromelain): A Review. Pak. J. Nutr. 2008, 7, 513–520. [CrossRef]
- Bui, C.H.; Seldin, E.B.; Dodson, T.B. Types, frequencies, and risk factors for complications after third molar extraction. J Oral Maxillofac Surg 2003, 61:1379. [CrossRef]
- Ogden, G.R.; Bissias, E.; Ruta, D.A.; et al. Quality of life following third molar removal: A patient versus professional perspective. Br Dent J 1998, 185:407. [CrossRef]
- Maurer, H. Bromelain: Biochemistry, pharmacology and medical use. Cell. Mol. Life Sci. 2001, 58, 1234–1245. [CrossRef]



| Variable | Bromelain (n=14) | Brome-Inf® (n=14) | Placebo (n=14) | Total | P value |
|---|---|---|---|---|---|
| Age (year) | 22.4 ± 4.9 | 22.9 ± 4.5 | 23.1 ± 4.1 | 22.8± 4.5 | n.s. |
| Gender | |||||
| Male | 5 | 6 | 8 | 19 | n.a. |
| Female | 8 | 7 | 8 | 23 | n.a. |
| BMI (Kg/m2) | 24.4 ± 0.2*** | 24.6 ± 0.2 | 24.8 ± 0.3 | 24.6 ± 0.2 | Placebo vs Bromelain P=0.0002 Placebo vs Brome-Inf® P=0.0963 n.s. Bromelain vs Brome-Inf® P=0.0963 n.s. |
| Operation time (min) | 31.2 ± 14.1 | 32.7 ± 18.2 | 31.5 ± 17.4 | 31.8 ± 16.5 | n.s. |
| Variable | Placebo (n=14) | Bromelain (n=14) | Brome-Inf® (n=14) | P value |
|---|---|---|---|---|
| VAS-10 | ||||
| Day-1 | 3.857 ±0.462 | 2.286 ±0.529**** | 2.121 ±0.387**** | Placebo vs Bromelain P<0.0001 Placebo vs Brome-Inf® P<0.0001 Bromelain vs Brome-Inf® P>0.9999 n.s. |
| Day-3 | 2.836 ±0.325 | 1.514 ±0.419**** | 1.457 ±0.238**** | Placebo vs Bromelain P<0.0001 Placebo vs Brome-Inf® P<0.0001 Bromelain vs Brome-Inf® P>0.9999 n.s. |
| Day-7 | 1.629 ±0.190 | 0.407 ±0.144**** | 0.450 ±0.129**** | Placebo vs Bromelain P<0.0001 Placebo vs Brome-Inf® P<0.0001 Bromelain vs Brome-Inf® P>0.9999 n.s. |
| D1 vs D3; D3 vs D7; D1 vs D7: P<0.0001§§§§) | (D1 vs D3; D3 vs D7; D1 vs D7: P<0.0001§§§§) |
(D1 vs D3; D3 vs D7; D1 vs D7: P<0.0001§§§§) |
||
| Swelling | ||||
| Day-1 | 8.193 ±0.329 | 7.7779 ±0.345** | 7.929 ±0.264 | Placebo vs Bromelain P=0.0037 Placebo vs Brome-Inf® P=0.0969 n.s. Bromelain vs Brome-Inf® P=0.6440 n.s. |
| Day-3 | 4.236 ±0.448 | 3.093 ±0.329**** | 3.257 ±0.253**** | Placebo vs Bromelain P<0.0001 Placebo vs Brome-Inf® P<0.0001 Bromelain vs Brome-Inf® P=0.6775 n.s. |
| Day-7 | 1.843 ±0.214 | 1.207 ±0.219**** | 1.243 ±0.320**** | Placebo vs Bromelain P<0.0001 Placebo vs Brome-Inf® P<0.0001 Bromelain vs Brome-Inf® P>0.9999 n.s. |
| D1 vs D3; D3 vs D7; D1 vs D7: P<0.0001§§§§ | D1 vs D3; D3 vs D7; D1 vs D7: P<0.0001§§§§ |
D1 vs D3; D3 vs D7; D1 vs D7: P<0.0001§§§§ |
||
| Trismus | ||||
| Day-1 | 13.1 ±3.7 | 13.4 ±3.9 | 13.1 ±3.7 | Placebo vs Bromelain P>0.9999 n.s. Placebo vs Brome-Inf® P>0.9999 n.s. Bromelain vs Brome-Inf® P>0.9999 n.s. |
| Day-3 | 8.9 ±2.1 | 7.5 ±2.3 | 7.8 ±2.5 | Placebo vs Bromelain P=0.3488 n.s. Placebo vs Brome-Inf® P=0.6431 n.s. Bromelain vs Brome-Inf® P>0.9999 n.s. |
| Day-7 | 5.4 ±1.5 | 4.3 ±1.1 | 4.6 ±1.2 | Placebo vs Bromelain P=0.0850 n.s. Placebo vs Brome-Inf® P=0.3171 Bromelain vs Brome-Inf® P>0.9999 n.s. |
| D1 vs D3: P=0.0004§§§; D3 vs D7: P=0.0030§§; D1 vs D7: P<0.0001§§§§ |
D1 vs D3: P<0.0001§§§§;D3 vs D7: P=0.0095§§; D1 vs D7: P<0.0001§§§§ |
D1 vs D3: P<0.0001§§§§; D3 vs D7: P=0.0089§§; D1 vs D7: P<0.0001§§§§ |
||
| Rescue tablets of ibuprofen | 6.4 ±1.4 | 3.6 ±1.2**** | 3.2 ±1.4**** | Placebo vs Bromelain P<0.0001 Placebo vs Brome-Inf® P<0.0001 Bromelain vs Brome-Inf® P>0.9999 n.s. |
| Variable | Placebo (n=14) | Bromelain (n=14) | Brome-Inf® (n=14) | P value |
|---|---|---|---|---|
| Social | 0.9 ±0.3 | 0.4 ±0.2**** | 0.3 ±0.2**** | Placebo vs Bromelain: P<0.0001 Placebo vs Brome-Inf®: P<0.0001 Bromelain vs Brome-Inf®: P=0.8196 n.s. |
| Work | 1.1 ±0.4 | 0.6 ±0.4** | 0.4 ±0.3**** | Placebo vs Bromelain: P=0.0028 Placebo vs Brome-Inf®: P<0.0001 Bromelain vs Brome-Inf®: P=0.4809 n.s. |
| Eating | 8.1 ±1.7 | 5.7 ±1.0**** | 5.8 ±0.9**** | Placebo vs Bromelain: P<0.0001 Placebo vs Brome-Inf®: P<0.0001 Bromelain vs Brome-Inf®: P>0.9999 n.s. |
| Speech | 1.8 ±0.9 | 1.1 ±0.7**** | 1.2 ±0.6**** | Placebo vs Bromelain: P<0.0001 Placebo vs Brome-Inf®: P<0.0001 Bromelain vs Brome-Inf®: P>0.9999 n.s. |
| Sleep | 2.4 ±1.1 | 0.7 ±0.5**** | 0.9 ±0.4**** | Placebo vs Bromelain: P<0.0001 Placebo vs Brome-Inf®: P<0.0001 Bromelain vs Brome-Inf®: P>0.9999 n.s. |
| Appearance | 2.9 ±1.2 | 1.2 ±0.7**** | 1.5 ±0.8*** | Placebo vs Bromelain: P<0.0001 Placebo vs Brome-Inf®: P=0.0008 Bromelain vs Brome-Inf®: P>0.9999 n.s. |
| Total | 17.2 ±5.6 | 9.7 ±3.5*** | 10.1 ±3.2*** | Placebo vs Bromelain: P=0.0001 Placebo vs Brome-Inf®: P=0.0002 Bromelain vs Brome-Inf®: P>0.9999 n.s. |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).